Edesa Biotech

Yahoo Finance • last month

Vitiligo Clinical Trial Pipeline Accelerates as 18+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

New York, USA, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Vitiligo Clinical Trial Pipeline Accelerates as 18+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight The vitiligo treatment landscape is evolving with a shift tow... Full story

Yahoo Finance • 2 months ago

Edesa Biotech Reports Fiscal 3rd Quarter 2025 Results

TORONTO, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results... Full story

Yahoo Finance • 2 months ago

Edesa Biotech files $150M mixed securities shelf offering

* Edesa Biotech (NASDAQ:EDSA [https://seekingalpha.com/symbol/EDSA]) has filed to offer up to $150M in a mix of securities. * The offering may include common shares, preferred shares, warrants, debt securities, subscription rights, and... Full story

Yahoo Finance • 6 months ago

Edesa Biotech Announces Chief Financial Officer Transition

TORONTO, April 04, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today announced the appointment... Full story

Yahoo Finance • 7 months ago

Edesa Biotech Reports Fiscal 1st Quarter 2025 Results

TORONTO, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results... Full story

Yahoo Finance • 7 months ago

Edesa Biotech Announces $15.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Financing led by Velan Capital with participation from new and existing healthcare-focused institutional investors and insidersCapital raise to fund Edesa’s CXCL10 antibody program through the end of fiscal 2026 TORONTO, Feb. 13, 2025 (... Full story